Slide 1: Resilient into the Future of Biopharma R&D
Resilient into the Future of Biopharma R&D Evotec SE, 9M 2023 results call, 08 November 2023
Slide 2: Disclaimer
Disclaimer This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the “Company”, “we,” “our” or “us”). This presentation is made pursuant to Sec
Slide 3: Welcome! The Management Team
Welcome! The Management Team Werner Lanthaler Laetitia Rouxel Matthias Evers CEO CFO CBO Craig Johnstone Cord Dohrmann COO CSO PAGE 3
Slide 4: Agenda
Agenda 1. Highlights 2. Financials 9M 2023 & Guidance 2023 3. Science & Operations 9M 2023 4. ESG, Outlook PAGE 4
Slide 5: Going strong again, with the cyber-attack in the rear mirror
Going strong again, with the cyber-attack in the rear mirror Highlights & lowlights in Q3 / 9M • 9M 2023 with 14% revenue growth1; EBITDA growth of 13%, despite cyber-attack • Next major collaboration agreement with BMS in Neurodegeneration in June • Continued validation of Just – Evotec Biologics;
Slide 6: Action Plan 2025 on track
Action Plan 2025 on track Action Plans in numbers 2021 2018 2012 2009 Action Plan 2025 Action Plan 2022 Leadership in data, science, Action Plan 2016 Aspire global leadership Action Plan 2012 Build innovation seeds multimodality & access Restructure for growth 2010 2015 2020 2025 • Revenues: € 55 m
Slide 7: Agenda
Agenda 1. Highlights 2. Financials 9M 2023 & Guidance 2023 3. Science & Operations 9M 2023 4. ESG, Outlook PAGE 7
Slide 8: Strong Q1 performance sees continuation in Q3 after cyber-attack
Strong Q1 performance sees continuation in Q3 after cyber-attack 9M 2023 revenue composition by quarters/months (€ m) Business dynamics back in € m ~70 (net) • Q1 2023 first quarter ever with revenues exceeding € 200 m • Just – Evotec Biologics ahead of 196.3 plan based on closing of tech- ~70 (net)
Slide 9: Strong balance sheet as solid base for strategy execution
Strong balance sheet as solid base for strategy execution Balance sheet and Cash-flow items 9M 2023 – Evotec SE & subsidiaries Balance sheet total Equity ratio Operating Cash-flow in € m vs. 31 Dec 2022 in % vs. 31 Dec 2022 in € m vs. 9M 2022 2,257.2 2,254.5 52.6 50.6 236.6 15.2 Net Debt ratio Liqui
Slide 10: 9M 2023 – continuing double digit growth
9M 2023 – continuing double digit growth Income statement KPIs 9M 2023 – Evotec SE and subsidiaries in € m1 9M 2023 9M 2022 Change Drivers Revenues 580.1 510.8 14% Precision Medicine and Biologics of which Just – Evotec Biologics (JEB) 74.1 27.9 >160% Sandoz alliance & 2nd DoD contract Milestones, U
Slide 11: Recovery in H2 ongoing – good indications into 2024
Recovery in H2 ongoing – good indications into 2024 Guidance 2023 unchanged Guidance 20234 YE 2022 Comments At least stable Group revenues € 750– 790 m € 751.2 m despite approx. € 70 m (at constant fx-rates1) (€ 765 – 805 m) one-off effect Unpartnered R&D2 € 60 – 70 m € 69.9 m Stable Mitigation of l
Slide 12: Identified efficiencies
Identified efficiencies Better, safer, more agile Bouncing back better • Leaner processes 1 Value Protection Programme (VPP) − E.g. focused ERP-System1 build-out in UK and Toulouse • Headcount & Footprint optimisation − E.g. capacity optimisation / mobility in Marcy (Lyon) • Focused investments − E.
Slide 13: Agenda
Agenda 1. Highlights 2. Financials 9M 2023 & Guidance 2023 3. Science & Operations 9M 2023 4. ESG, Outlook PAGE 13
Slide 14: Paradigm-shifting platforms are key growth drivers
Paradigm-shifting platforms are key growth drivers Revenue distribution 9M 2022 versus 9M 2023 9M 2022 9M 2023 • 9M 2023 Group revenue € 510.8 m € 580.1 m growth 14% despite high double-digit impact from 20% cyber-attack 29% • PanOmics-based revenues growth ~70% 4% • Just – Evotec Biologics 5% 52% r
Slide 15: Pipeline building with PanOmics is just at the beginning
Pipeline building with PanOmics is just at the beginning Shared economy model KPIs Total R&D costs since 2010 About € 2.5 m invested per partnered project - € ~450 M Most projects break-even well before clinical trials Total number of pharma deals / partnered product opportunities >140 partnered pro
Slide 16: The growing “iceberg” of first & best-in-class treatment options
The growing “iceberg” of first & best-in-class treatment options >140 co-owned projects Inflammation & Neuroscience & pain Oncology Metabolic diseases Immunology1 Virology, Anti-bacterial & Global health Approved SK Bio Ph III Jingxin Ph II Carrick Topas Clinical Centrexion ND Carrick Bayer Ph I BMS
Slide 17: Co-owned pipeline building progressing
Co-owned pipeline building progressing Selected pipeline news within next 12-24 months Phase III & registration (CHN) JingXin in insomnia (EVT201) Initiation Phase II with BMS in CNS (EVT8683) Initiation Phase II with Bayer in kidney disease, targeting Semaphorin-3A (“Sema3A”) Phase II data with Kaz
Slide 18: J.POD – the paradigm shift to continuous manufacturing
J.POD – the paradigm shift to continuous manufacturing Progress and status Ground-breaking for second new biologics facility "J.POD Toulouse“ in H2 2022 Building of shell and installation of PODs completed – on track for completion in H2 2024 J.POD Toulouse – Shell completed (November 2023) Starting
Slide 19: Just – Evotec Biologics
Just – Evotec Biologics Key achievements 2021-2023 Closed Sales Key progress in € m >850 Up to US$ 640 m for development work plus massive upside Anti-Plague mAb develop- ment programme >8x Development programme for anti-Orthopoxvirus mAb candidates 3x >100 First phase III trial in 31 H2 2024 for tr
Slide 20: Agenda
Agenda 1. Highlights 2. Financials 9M 2023 & Guidance 2023 3. Science & Operations 9M 2023 4. ESG, Outlook PAGE 20
Slide 21: Near-term science-based targets validated & approved
Near-term science-based targets validated & approved First goal achieved Science-based targets balancing growth and responsibility for the planet Commu- • 100% Renewable electricity Commit Develop Submit Disclose by 2026 (LTI goal 2023) nicate • 50.4% reduction of Scope 1 and 2 emissions by 2032, de
Slide 22: The work gets visible
The work gets visible Improved perception by all relevant rating agencies 2019 2020 2021 2022 2023 0 100 43 48 52 52 60 D- B- A+ C- C- C C “Prime” CCC AAA BBB BBB A AA AA +40 Under 0 – 18.8 18.1 18.1 review 0 100 24 28 30 30 38 PAGE 22
Slide 23: Keeping the promise
Keeping the promise ESG & Sustainability – Goals 2023 and status • Environment Approve and implement the SBTi initiative action plan at all Evotec sites and invest one percent of 2022 revenues to achieve SBTi targets – on target • Social Conduct engagement survey in 2023. Define and communicate a ma
Slide 24: Great expertise and governance in challenging times
Great expertise and governance in challenging times Rupert Vessey • Rupert Vessey is Chief Scientist and Executive Partner at Flagship Pioneering • Rupert served as Executive Vice President and President, Research at Celgene and later BMS (2015 – 2022) • From 2005 to 2015, Rupert spent ten years at
Slide 25: Executing to accelerate growth along Action Plan 2025
Executing to accelerate growth along Action Plan 2025 Selected major newsflow 2023 PanOmics • New strategic partnerships and expansions of co-owned alliances • New clinical trial initiations, e.g. Bayer • Significant progress of later stage co-owned pipeline iPSCs • New strategic partnerships, e.g.,
Slide 26: Upcoming important dates
Upcoming important dates Financial calendar 2023/2024 2nd Capital Markets Day 2023 15 November 2023 Jefferies Healthcare Conference, London 16 November 2023 German Equity Forum, Frankfurt/Main 27 November 2023 Berenberg European Conference, Pennyhill Park 06 December 2023 FY 2023 results / Sustainab
Slide 27: Looking forward to seeing you in Hamburg next week
Looking forward to seeing you in Hamburg next week CMD 2023 – 15 November PAGE 27
Slide 28: pREscaRcHnevensTors
pREscaRcHnevensTors
Slide 29: Volker Braun, Investor Relations & ESG
Volker Braun SVP Head of Global Investor Relations & ESG +49 (0) 151 1940 5058 (m) volker.braun@evotec.com www.evotec.com